The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation

DSpace/Manakin Repository

The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation

Citable link to this page

 

 
Title: The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation
Author: Tremblay, Annie M.; Missiaglia, Edoardo; Galli, Giorgio G.; Hettmer, Simone; Urcia, Roby; Carrara, Matteo; Judson, Rebekah M; Thway, Khin; Nadal, Gema; Selfe, Joanna L.; Murray, Graeme; Calogero, Raffaele A.; De Bari, Cosimo; Zammit, Peter S.; Delorenzi, Mauro; Wagers, Amy Jo; Shipley, Janet; Wackerhage, Henning; Camargo, Fernando D.

Note: Order does not necessarily reflect citation order of authors.

Citation: Tremblay, Annie M., Edoardo Missiaglia, Giorgio G. Galli, Simone Hettmer, Roby Urcia, Matteo Carrara, Robert N. Judson, et al. 2014. “The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation.” Cancer Cell 26 (2) (August): 273–287. doi:10.1016/j.ccr.2014.05.029.
Access Status: Full text of the requested work is not available in DASH at this time (“dark deposit”). For more information on dark deposits, see our FAQ.
Full Text & Related Files:
Abstract: The role of the Hippo pathway effector YAP1 in soft tissue sarcomas is poorly defined. Here we report that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS). In mice, sustained YAP1 hyperactivity in activated, but not quiescent, satellite cells induces ERMS with high penetrance and short latency. Via its transcriptional program with TEAD1, YAP1 directly regulates several major hallmarks of ERMS. YAP1-TEAD1 upregulate pro-proliferative and oncogenic genes and maintain the ERMS differentiation block by interfering withMYOD1and MEF2 pro-differentiation activities. Normalization of YAP1 expression reduces tumor burden in human ERMS xenografts and allows YAP1-driven ERMS to differentiate in situ. Collectively, our results identify YAP1 as a potent ERMS oncogenic driver and a promising target for differentiation therapy.
Published Version: doi:10.1016/j.ccr.2014.05.029
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33167448
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters